Table 1 Correlation between clinicopathological patient characteristics and the expression of insulin-like growth factor receptor 1 (IGF1R) in tumor cells. (a) Fisher’s exact test (b) Kendall’s tau test (c) Log-rank test. Abbreviations: n.c. = not calculated. * p values having lost significance according to the Siemes (Benjamini-Hochberg) procedure for multiple testing
From: Questioning the IGF1 receptor’s assigned role in CRC – a case for rehabilitation?
Total | Membranous IGF1R expression | Cytoplasmic IGF1R expression | ||||
|---|---|---|---|---|---|---|
lowHScore ≤ 10 | highHScore > 10 | lowHScore < 90 | highHScore ≥ 90 | |||
n(%) | n(%) | n(%) | n(%) | n(%) | ||
Gender | n p-Value (a) | 1499 | 1499 | 0.836 | 1499 | 0.350 |
Male | 769 (51.3) | 398 (51.8) | 371 (48.2) | 356 (46.3) | 413 (53.7) | |
Female | 730 (48.7) | 373 (51.1) | 357 (48.9) | 320 (43.8) | 410 (56.2) | |
Age Group | n p-Value (a) | 1499 | 1499 | 0.877 | 1499 | 0.324 |
< 71 years | 738 (49.2) | 378 (51.2) | 360 (48.8) | 323 (43.8) | 415 (56.2) | |
≥ 71 years | 761 (50.8) | 393 (51.6) | 368 (48.4) | 353 (46.4) | 408 (53.6) | |
Localization | n p-Value (a) | 1422 | 1422 | < 0.001 | 1422 | < 0.001 |
Left-sided | 860 (60.5) | 394 (45.8) | 466 (54.2) | 347 (40.3) | 513 (59.7) | |
Right-sided | 562 (39.5) | 336 (59.8) | 226 (40.2) | 287 (51.1) | 275 (48.9) | |
T-Category | n p-Value (b) | 1499 | 1499 | 0.678 | 1499 | < 0.001 |
T1 | 71 (4.7) | 41 (57.7) | 30 (42.3) | 26 (36.6) | 45 (63.4) | |
T2 | 316 (21.1) | 158 (50.0) | 158 (50.0) | 115 (36.4) | 201 (63.6) | |
T3 | 863 (57.6) | 448 (51.9) | 415 (48.1) | 407 (47.2) | 456 (52.8) | |
T4a/b | 249 (16.6) | 124 (49.8) | 125 (50.2) | 128 (51.4) | 121 (48.6) | |
T-Category (grouped) | n p-Value (a) | 1499 | 1499 | 1.000 | < 0.001 | |
T1/T2 | 387 (25.8) | 199 (51.4) | 188 (48.6) | 141 (36.4) | 246 (63.6) | |
T3/T4a/T4b | 1112 (74.2) | 572 (51.4) | 540 (48.6) | 535 (48.1) | 577 (51.9) | |
N-Category | n p-Value (b) | 1480 | 1480 | 0.197 | 1480 | 0.047* |
N0 | 821 (55.5) | 429 (52.3) | 392 (47.7) | 354 (43.1) | 467 (56.9) | |
N1a/b/c | 316 (21.3) | 171 (54.1) | 145 (45.9) | 140 (44.3) | 176 (55.7) | |
N2a/b | 343 (23.2) | 160 (46.6) | 183 (53.4) | 172 (50.1) | 171 (49.9) | |
N-Category | n p-Value (a) | 1480 | 1480 | 0.464 | 1480 | 0.115 |
N0 | 821 (55.5) | 429 (52.3) | 392 (47.7) | 354 (43.1) | 467 (56.9) | |
N+ (N1a/b/c, N2a/b) | 659 (44.5) | 331 (50.2) | 328 (49.8) | 312 (47.3) | 347 (52.7) | |
M-Category | n p-Value (a) | 1499 | 1499 | 0.331 | 1499 | 0.871 |
M1 | 172 (11.5) | 82 (47.7) | 90 (52.3) | 79 (45.9) | 93 (54.1) | |
MX | 1327 (88.5) | 689 (51.9) | 638 (48.1) | 597 (45.0) | 730 (55.0) | |
UICC Stage | n p-Value (b) | 1499 | 1499 | 0.358 | 1499 | 0.025* |
I | 310 (20.6) | 161 (51.9) | 149 (48.1) | 116 (37.4) | 194 (62.6) | |
IIA/B/C | 494 (33.0) | 261 (52.8) | 233 (47.2) | 231 (46.8) | 263 (53.2) | |
IIIA/B/C | 524 (35.0) | 268 (51.1) | 256 (48.9) | 251 (47.9) | 273 (52.1) | |
IVA/B | 171 (11.4) | 81 (47.4) | 90 (52.6) | 78 (45.6) | 93 (54.4) | |
L-Category | n p-Value (a) | 1499 | 1499 | 0.187 | 1499 | 0.002 |
L0 | 1131 (75.5) | 593 (52.4) | 538 (47.6) | 484 (42.8) | 647 (57.2) | |
L1 | 368 (24.5) | 178 (48.4) | 190 (51.6) | 192 (52.2) | 176 (47.8) | |
V-Category | n p-Value (a) | 1498 | 1498 | 1.000 | 1498 | 0.834 |
V0 | 1400 (93.5) | 721 (51.5) | 679 (48.5) | 721 (51.5) | 679 (48.5) | |
V1 | 98 (6.5) | 50 (51.0) | 48 (49.0) | 50 (51.0) | 48 (49.0) | |
Pn-Category | n p-Value (a) | 677 | 677 | 1.000 | 677 | 0.512 |
Pn0 | 638 (94.2) | 338 (53.0) | 300 (47.0) | 281 (44.0) | 357 (56.0) | |
Pn1 | 39 (5.8) | 21 (53.8) | 18 (46.2) | 15 (38.5) | 24 (61.5) | |
Grading | n p-Value (a) | 1476 | 1476 | 0.738 | 1176 | 0.002 |
Low grade (G1/G2) | 1202 (81.4) | 616 (51.2) | 586 (48.8) | 521 (43.3) | 681 (56.7) | |
High grade (G3/G4) | 274 (18.6) | 144 (52.6) | 130 (47.4) | 147 (53.6) | 127 (46.4) | |
R-Status | n p-Value (a) | 1458 | 1458 | 0.097 | 1458 | 0.408 |
R0 | 1421 (97.5) | 739 (52.0) | 682 (48.0) | 640 (45.0) | 781 (55.0) | |
R1/R2 | 37 (2.5) | 14 (37.8) | 23 (62.2) | 14 (37.8) | 23 (62.2) | |
Mismatch repair protein (MMR) status | n p-Value (a) | 487 | 487 | 0.002 | 487 | 0.016* |
MMR proficient | 392 (80.5) | 193 (49.2) | 199 (50.8) | 171 (43.6) | 221 (56.4) | |
MMR deficient | 95 (19.5) | 64 (67.4) | 31 (32.6) | 55 (57.9) | 40 (42.1) | |
KRAS mutation status | n p-Value (a) | 26 | 26 | 0.453 | 26 | 0.683 |
KRAS wild-type | 14 (53.8) | 7 (50.0) | 7 (50.0) | 4 (28.6) | 10 (71.4) | |
KRAS mutation | 12 (46.2) | 8 (66.7) | 4 (33.3) | 5 (41.7) | 7 (58.3) | |
Overall Survival [Months] | p-Value (c) | 1495 | 0.648 | 1495 | 0.051 | |
Total / Events / Censored | 1495/737/758 | 770/378/392 | 725/359/366 | 672/352/320 | 823/385/438 | |
Median Survival | 92.4 | 95.5 | 85.8 | 70.4 | 119.6 | |
95% C.I. | 114.8–125.2 | n.c. | n.c. | 48.2–92.7 (+ − 11.4) | n.c. | |
Tumour Specific Survival [Months] | p-Value (c) | 1481 | 0.193 | 1481 | 0.093 | |
Total / Events / Censored | 1481/501/980 | 763/246/517 | 718/255/463 | 665/240/425 | 816/261/555 | |
Median Survival | n.c. | n.c. | n.c. | n.c. | n.c. | |
95% C.I. | 141.6–152.1 | n.c. | n.c. | n.c. | n.c. | |